These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 30794051)

  • 1. A phase I trial of WRSS1, a
    Raqib R; Sarker P; Zaman K; Alam NH; Wierzba TF; Maier N; Talukder K; Baqui AH; Suvarnapunya AE; Qadri F; Walker RI; Fix A; Venkatesan MM
    Hum Vaccin Immunother; 2019; 15(6):1326-1337. PubMed ID: 30794051
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical Trial of an Oral Live Shigella sonnei Vaccine Candidate, WRSS1, in Thai Adults.
    Pitisuttithum P; Islam D; Chamnanchanunt S; Ruamsap N; Khantapura P; Kaewkungwal J; Kittitrakul C; Luvira V; Dhitavat J; Venkatesan MM; Mason CJ; Bodhidatta L
    Clin Vaccine Immunol; 2016 Jul; 23(7):564-75. PubMed ID: 27146000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers.
    Orr N; Katz DE; Atsmon J; Radu P; Yavzori M; Halperin T; Sela T; Kayouf R; Klein Z; Ambar R; Cohen D; Wolf MK; Venkatesan MM; Hale TL
    Infect Immun; 2005 Dec; 73(12):8027-32. PubMed ID: 16299296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional Antibodies and Innate Immune Responses to WRSS1, a Live Oral Shigella sonnei Vaccine Candidate, in Bangladeshi Adults and Children.
    Sarker P; Mily A; Ara A; Haque F; Maier N; Wierzba TF; Walker RI; Venkatesan MM; Raqib R
    J Infect Dis; 2021 Dec; 224(12 Suppl 2):S829-S839. PubMed ID: 34374425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection.
    Barnoy S; Baqar S; Kaminski RW; Collins T; Nemelka K; Hale TL; Ranallo RT; Venkatesan MM
    Vaccine; 2011 Aug; 29(37):6371-8. PubMed ID: 21596086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody in Lymphocyte Supernatant (ALS) responses after oral vaccination with live Shigella sonnei vaccine candidates WRSs2 and WRSs3 and correlation with serum antibodies, ASCs, fecal IgA and shedding.
    Venkatesan MM; Ballou C; Barnoy S; McNeal M; El-Khorazaty J; Frenck R; Baqar S
    PLoS One; 2021; 16(11):e0259361. PubMed ID: 34793505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults.
    Kotloff KL; Taylor DN; Sztein MB; Wasserman SS; Losonsky GA; Nataro JP; Venkatesan M; Hartman A; Picking WD; Katz DE; Campbell JD; Levine MM; Hale TL
    Infect Immun; 2002 Apr; 70(4):2016-21. PubMed ID: 11895966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial.
    McKenzie R; Walker RI; Nabors GS; Van De Verg LL; Carpenter C; Gomes G; Forbes E; Tian JH; Yang HH; Pace JL; Jackson WJ; Bourgeois AL
    Vaccine; 2006 May; 24(18):3735-45. PubMed ID: 16095766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh.
    Rahman KM; Arifeen SE; Zaman K; Rahman M; Raqib R; Yunus M; Begum N; Islam MS; Sohel BM; Rahman M; Venkatesan M; Hale TL; Isenbarger DW; Sansonetti PJ; Black RE; Baqui AH
    Vaccine; 2011 Feb; 29(6):1347-54. PubMed ID: 21040694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.
    Cohen D; Atsmon J; Artaud C; Meron-Sudai S; Gougeon ML; Bialik A; Goren S; Asato V; Ariel-Cohen O; Reizis A; Dorman A; Hoitink CWG; Westdijk J; Ashkenazi S; Sansonetti P; Mulard LA; Phalipon A
    Lancet Infect Dis; 2021 Apr; 21(4):546-558. PubMed ID: 33186516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult Subjects.
    Chakraborty S; Harro C; DeNearing B; Bream J; Bauers N; Dally L; Flores J; Van de Verg L; Sack DA; Walker R
    Clin Vaccine Immunol; 2016 Apr; 23(4):315-25. PubMed ID: 26865592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial.
    Launay O; Sadorge C; Jolly N; Poirier B; Béchet S; van der Vliet D; Seffer V; Fenner N; Dowling K; Giemza R; Johnson J; Ndiaye A; Vray M; Sansonetti P; Morand P; Poyart C; Lewis D; Gougeon ML
    Vaccine; 2009 Feb; 27(8):1184-91. PubMed ID: 19135496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I trial to evaluate the safety and immunogenicity of WRSs2 and WRSs3; two live oral candidate vaccines against Shigella sonnei.
    Frenck RW; Baqar S; Alexander W; Dickey M; McNeal M; El-Khorazaty J; Baughman H; Hoeper A; Barnoy S; Suvarnapunya AE; Kaminski RW; Venkatesan MM
    Vaccine; 2018 Aug; 36(32 Pt B):4880-4889. PubMed ID: 30037478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study.
    Riddle MS; Kaminski RW; Di Paolo C; Porter CK; Gutierrez RL; Clarkson KA; Weerts HE; Duplessis C; Castellano A; Alaimo C; Paolino K; Gormley R; Gambillara Fonck V
    Clin Vaccine Immunol; 2016 Dec; 23(12):908-917. PubMed ID: 27581434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shigella-specific antibodies in the first year of life among Zambian infants: A longitudinal cohort study.
    Chisenga CC; Bosomprah S; Simuyandi M; Mwila-Kazimbaya K; Chilyabanyama ON; Laban NM; Bialik A; Asato V; Meron-Sudai S; Frankel G; Cohen D; Chilengi R
    PLoS One; 2021; 16(5):e0252222. PubMed ID: 34043697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe.
    Launay O; Lewis DJM; Anemona A; Loulergue P; Leahy J; Sciré AS; Maugard A; Marchetti E; Zancan S; Huo Z; Rondini S; Marhaba R; Finco O; Martin LB; Auerbach J; Cohen D; Saul A; Gerke C; Podda A
    EBioMedicine; 2017 Aug; 22():164-172. PubMed ID: 28735965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel.
    Passwell JH; Harlev E; Ashkenazi S; Chu C; Miron D; Ramon R; Farzan N; Shiloach J; Bryla DA; Majadly F; Roberson R; Robbins JB; Schneerson R
    Infect Immun; 2001 Mar; 69(3):1351-7. PubMed ID: 11179298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.
    Passwell JH; Ashkenazi S; Harlev E; Miron D; Ramon R; Farzam N; Lerner-Geva L; Levi Y; Chu C; Shiloach J; Robbins JB; Schneerson R;
    Pediatr Infect Dis J; 2003 Aug; 22(8):701-6. PubMed ID: 12913770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model.
    Barry EM; Wang J; Wu T; Davis T; Levine MM
    Vaccine; 2006 May; 24(18):3727-34. PubMed ID: 16169130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain.
    Ranallo RT; Thakkar S; Chen Q; Venkatesan MM
    Vaccine; 2007 Mar; 25(12):2269-78. PubMed ID: 17229494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.